Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$8.67 USD

8.67
338,446

+0.11 (1.29%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $8.68 +0.01 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered

by Zacks Equity Research

ALC ends the first quarter of 2025 on a disappointing note.

Zacks Equity Research

Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase

by Zacks Equity Research

PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.

Zacks Equity Research

QIAGEN Stock Gains Following the Acquisition of Genoox

by Zacks Equity Research

QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio.

Zacks Equity Research

Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised

by Zacks Equity Research

PODD delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up

by Zacks Equity Research

Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.

Zacks Equity Research

GMED Q1 Earnings & Revenues Miss, '25 EPS View Down, Stock Falls

by Zacks Equity Research

GMED's first-quarter 2025 weak performance reflects soft Enabling Technology deal closures.

Zacks Equity Research

Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up

by Zacks Equity Research

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.

Zacks Equity Research

Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips

by Zacks Equity Research

ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

Phibro Q3 Earnings Top Estimates, Stock Up, 2025 EPS Outlook Raised

by Zacks Equity Research

PAHC's third-quarter fiscal 2025 results reflect the strength of the Animal Health segment.

Zacks Equity Research

Bruker Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Crash

by Zacks Equity Research

Bruker delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

EYE Q1 Earnings and Revenues Beat, Gross Margin Up, Stock Surges

by Zacks Equity Research

Continued strength in Managed Care aids National Vision's first-quarter 2025 performance.

Zacks Equity Research

QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up

by Zacks Equity Research

QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.

Zacks Equity Research

Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket

by Zacks Equity Research

TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.

Zacks Equity Research

CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up

by Zacks Equity Research

Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

Omnicell Q1 Earnings & Revenues Beat, '25 EPS View Down, Stock Up

by Zacks Equity Research

OMCL posts better-than-expected top and bottom-line results for the first quarter of 2025.

Zacks Equity Research

MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook

by Zacks Equity Research

Myriad Genetics delivers a narrower-than-expected loss in the first quarter of 2025.

Zacks Equity Research

Integra Q1 Earnings Miss Estimates, Stock Down, '25 EPS Outlook Cut

by Zacks Equity Research

IART's first-quarter 2025 earnings lag the consensus mark. Q2 revenue projections are bleak.

Zacks Equity Research

NVST Stock Up on Q1 Earnings and Revenue Beat, Margins Crash

by Zacks Equity Research

Envista delivers better-than-expected top and bottom-line results for the first quarter of 2025.

Zacks Equity Research

ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket

by Zacks Equity Research

Zimmer Biomet reports solid first-quarter performance across its geographic regions. However, contraction in its operating margin is a concern.

Zacks Equity Research

Henry Schein Q1 Earnings Top Estimates, Revenues Miss, Stock Falls

by Zacks Equity Research

HSIC ends the first quarter of 2025 on a mixed note.

Zacks Equity Research

Teleflex Q1 Earnings Beat, '25 EPS View Down, Stock Up

by Zacks Equity Research

TFX benefits from a diversified product portfolio in the first quarter of 2025, with strength in the Surgical and Interventional segments.

Zacks Equity Research

AngioDynamics (ANGO) Down 6.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up

by Zacks Equity Research

Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.

Zacks Equity Research

BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket

by Zacks Equity Research

Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.

Zacks Equity Research

EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised

by Zacks Equity Research

Exact Sciences ends the first quarter of 2025 on a solid note.